Floatz logo

Methoxyamine

Lung Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

63 Active assets in the Lung Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Guangdong Association of Clinical Trials
Phase 3BBB
Cyclophosphamide
Anusha Kalbasi
Phase 2BBB
Cis-Diamminedichloroplatinum Ii
Guangdong Association of Clinical Trials
Phase 3BB
Etoposide
Guangdong Association of Clinical Trials
Phase 3BB
Nivolumab
Emory University
Phase 3BB

View all 50 →

Same molecule, other indications

Methoxyamine is also rated in:

lung large cell carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
neoplasmActive
B
Indicative · Phase 1/2
59 / 100
View asset →
adult glioblastomaDormant
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →